Fulgent Genetics Priced, Nasdaq: FLGT

Offers genetic testing for over 7,500 conditions.

Industry: Health Care

Latest Trade: $11.10 +0.06 (+0.5%)

First Day Return: +2.0%

Return from IPO: +22.7%

Industry: Health Care

We are a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. We have developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows us to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. We believe our current test menu offers more genes for testing than our competitors in today’s market, which enables us to provide expansive options for test customization and clinically actionable results. Our current test menu includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels that collectively test for more than 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders.
more less
IPO News for Fulgent Genetics
more
IPO Data
IPO File Date 09/02/2016
Offer Price $9.00
Price Range $9.00 - $11.00
Offer Shares (mm) 4.2
Deal Size ($mm) $38
IPO Data
IPO Date 09/28/2016
Offer Price $9.00
Price Range $9.00 - $11.00
Offer Shares (mm) 4.2
Deal Size ($mm) $38
Underwriters
more
Company Data
Headquarters Temple City, CA
Founded 2011
Employees 55
Website www.fulgentgenetics.com